155 related articles for article (PubMed ID: 34983646)
1. Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.
Bello-Manga H; Haliru L; Tabari AM; Farouk B; Suleiman A; Bahago GY; Sani AM; Bauman AA; DeBaun MR; King AA
BMC Res Notes; 2022 Jan; 15(1):1. PubMed ID: 34983646
[TBL] [Abstract][Full Text] [Related]
2. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
[TBL] [Abstract][Full Text] [Related]
3. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
4. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
5. Primary Prevention of Stroke in Children With Sickle Cell Anemia in Nigeria: Protocol for a Mixed Methods Implementation Study in a Community Hospital.
Bello-Manga H; Haliru L; Ahmed KA; Tabari AM; Farouk BU; Bahago GY; Kazaure AS; Muhammad AS; Gwarzo SA; Baumann AA; DeBaun MR; King AA
JMIR Res Protoc; 2022 Jun; 11(6):e37927. PubMed ID: 35700018
[TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
8. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
[TBL] [Abstract][Full Text] [Related]
10. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
[No Abstract] [Full Text] [Related]
11. Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa.
Ghafuri DL; Covert Greene B; Musa B; Gambo A; Sani A; Abdullahi S; Wudil BJ; Bello-Manga H; Gambo S; Ghafuri M; Cassell H; Neville K; Kirkham F; Kassim AA; Aliyu MH; DeBaun MR; Jordan LC
Pediatr Neurol; 2021 Dec; 125():9-15. PubMed ID: 34563875
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
[TBL] [Abstract][Full Text] [Related]
13. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
14. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
15. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
[TBL] [Abstract][Full Text] [Related]
16. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
18. PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
Debaun MR
Trans Am Clin Climatol Assoc; 2022; 132():236-248. PubMed ID: 36196180
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
[TBL] [Abstract][Full Text] [Related]
20. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]